quinazolines has been researched along with alfuzosin in 361 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (3.60) | 18.7374 |
| 1990's | 73 (20.22) | 18.2507 |
| 2000's | 166 (45.98) | 29.6817 |
| 2010's | 94 (26.04) | 24.3611 |
| 2020's | 15 (4.16) | 2.80 |
| Authors | Studies |
|---|---|
| Bianchetti, G; Costa, J; Garcia-Teresa, G; Morselli, P; Salva, P | 1 |
| Gilbey, MP; Marks, SA | 1 |
| de Boo, T; de la Rosette, JJ; Debruyne, FM; Karthaus, HF; van Kerrebroeck, PE | 1 |
| Hansen, BJ; Meyhoff, HH | 1 |
| Kondo, S; Morita, T | 1 |
| Attali, P; Delauche-Cavallier, MC; Teillac, P | 1 |
| Antonacci, A; Bombelli, M; Leto di Priolo, S; Libretti, A; Marazzi, ME; Pirrelli, A; Sega, R; Vulpis, V | 1 |
| Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A | 3 |
| Chapple, CR | 2 |
| Bauer, P; Carbin, BE; Friskand, M; Moyse, D | 1 |
| Buckingham, JC; Dashwood, MR; Ginsburg, J; Leposavic, G | 1 |
| Durand, A; Manoha, M; Rouchouse, A; Thenot, JP | 1 |
| Ramsay, JW; Scott, GI; Whitfield, HN | 1 |
| Jardin, A | 2 |
| Berard, EJ; Boucand, MH; Depassio, J; Fyon, JP | 1 |
| Bérard, E; Cramer, P; Depassio, J; Neveux, E; Régnier, F | 1 |
| Deering, AH; Harron, DW; McMahon, MT; Scott, MG; Shanks, RG | 1 |
| Krstulovic, AM; Vende, JL | 1 |
| Davies, IB; Sinclair, AJ; Warrington, SJ | 1 |
| Broquaire, M; Colafranceschi, C; Guinebault, P; Thénot, JP | 1 |
| Deering, AH; Harron, DW; McAloney, R; Mitchell, H; Shanks, RG | 1 |
| Cazor, JL; Cocco, G; Leto di Priolo, S; Priore, P; Sfrisi, C | 1 |
| Ramage, AG | 1 |
| Deering, AH; Harron, DW; Riddell, JG; Shanks, RG | 1 |
| Binet, JL; Cavero, I; Dumas, AP; Lefèvre-Borg, F; Manoury, PM | 1 |
| Angel, I; Jammes, D; Martin, D | 1 |
| Blondin, P; Buzelin, JM; Hebert, M | 1 |
| Hansen, BJ; Mensink, HJ; Meyhoff, HH; Nordling, J; Walter, S | 1 |
| Mensink, HJ | 1 |
| Ferretti, S; Larosa, M; Salsi, P; Simonazzi, M | 1 |
| Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A; Stalla-Bourdillon, A | 1 |
| Gentili, G; Mautone, A; Milani, M; Tucci, G | 1 |
| Antonelli, D; Belloni, M; Bernasconi, S; Buizza, C; Chisena, S; Mandressi, A; Zaroli, A | 1 |
| De Sy, W; Santoni, JP; Schulman, CC; Tomas, M; Vandendris, M | 1 |
| Brasso, K; Flyger, H; Hald, T; Hansen, BJ; Meyhoff, HH; Mortensen, S; Nordling, J; Schou, J; Thorup Andersen, J; Walter, S | 1 |
| Fitton, A; McTavish, D; Wilde, MI | 1 |
| Casadei, G; Martelli, A; Pacifico, P | 1 |
| Grange, JC; Lukacs, B; McCarthy, C | 1 |
| Bianchetti, G; Desager, JP; Harvengt, C; Rosenzweig, P | 1 |
| Carter, AJ; Greengrass, PM; Kenny, BA; Naylor, AM; Read, AM; Wyllie, MG | 1 |
| Benavides, J; Claustre, Y; Rouquier, L | 1 |
| Gautier, E; Hicks, PE; Langer, SZ; Lechaire, J; Lefèvre-Borg, F; Manoury, P; O'Connor, SE; Pierre, F; Pimoule, C; Schoemaker, H | 1 |
| Cavallini, G | 1 |
| Hansen, BJ | 1 |
| Portet-Brunet, L | 1 |
| Amarenco, G; Costa, P; Delauche-Cavallier, MC; Geffriaud, C; Perrigot, M; Stalla-Bourdillon, A | 1 |
| Flyger, H; Hansen, BJ; Mensink, HJ; Meyhoff, HH; Mortensen, S | 1 |
| Chalmers, DH; Kenny, BA; Miller, AM; Naylor, AM; O'Connell, J; Williamson, IJ | 1 |
| Blondin, P; Du Boys, B; Grippon, P; Lassale, C; Lukacs, B; MacCarthy, C | 1 |
| Jardin, A; Leplège, A; Lukacs, B; Thibault, P | 1 |
| Hansen, BJ; Larsen, EH; Mensink, HJ; Meyhoff, HH; Mogensen, P; Nordling, J | 1 |
| Auguet, M; Chabrier, PE; Guilmard, C | 1 |
| Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S | 1 |
| Andersson, KE; Lepor, H; Wyllie, MG | 1 |
| D'Armiento, M; Damiano, R; De Sio, M; Mattace Raso, D; Perdonà, S; Santonastaso, C | 1 |
| Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S; Santoni, JP | 1 |
| Lukacs, B | 1 |
| Casadei, G; Colombo, R; Di Silverio, F; Giberti, C; Martorana, G; Pacifico, P; Rigatti, P; von Heland, M | 1 |
| Fernández Arjona, M; Fernández Borrell, A; Gómez Sancha, F; Mínguez Martínez, R; Peinado Ibarra, F; Pereira Sanz, I | 1 |
| Boutkan, H; Breslau, PJ; Burger, DH; Kappetein, AP | 1 |
| Buzelin, JM; Fonteyne, E; Khan, A; Kontturi, M; Witjes, WP | 1 |
| Comet, D; Grange, JC; Lukacs, B; Thibault, P | 1 |
| Flyger, H; Hald, T; Hansen, BJ; Hendolin, N; Mensink, HJ; Mortensen, S; Nordling, J; Riehmann, M | 1 |
| de la Rosette, JJ; Debruyne, FM; Geffriaud, C; Vignoli, GC; Wijkstra, H; Witjes, WP; Zerbib, M | 1 |
| Matushevskiĭ, IA; Mazo, EB; Nikitin, IuIu | 1 |
| Kirby, RS | 1 |
| Comet, D; Grange, JC; Lukacs, B; McCarthy, C | 2 |
| Angel, I; Buzelin, JM; Delauche Cavallier, MC; Martin, D | 1 |
| Cologna, A; Kaplan, SA; Kohn, IJ; Martins, AC; Reis, RB; Suaid, HJ; Te, AE | 1 |
| Angel, I; Lluel, P; Martin, DJ; Pouyet, T; Rauch-Desanti, C | 1 |
| Colloi, D; Debruyne, FM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Jardin, A; McCarthy, C; Resel, L; Witjes, WP | 1 |
| Borras-Blasco, J; Navarro-Ruiz, A; Vela-Casasempere, P | 1 |
| Bèïque, L; Evans, MF; Por, CP | 1 |
| Djavan, B; Marberger, M | 1 |
| Comet, D; Grange, JC; Lukacs, B; Mc Carthy, C | 1 |
| Navarro-Blasco, FJ | 1 |
| Claes, H; De Reijke, TM; Folkestad, B; Höfner, K; Speakman, MJ | 1 |
| Daruwala, PD; Hargreave, TB; McNeill, SA; Mitchell, ID; Shearer, MG | 1 |
| Fu, SX; Li, YS; Ren, LM; Wu, ZJ; Yang, ZH | 1 |
| Jardin, A; Laval, KU; van Cangh, P; van Kerrebroeck, P | 1 |
| Comet, D; Grange, JC; Lukacs, B | 1 |
| Alfaro, V; Badiella, L; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M | 1 |
| Gascón, A; Pina, MA; Thomson, C; Valdearcos, S; Zabala, S | 1 |
| Ausín, I; Barajas, R; Gabriel, R; Vela Navarrete, R | 1 |
| Fourcade, RO | 1 |
| Clifford, GM; Farmer, RD | 1 |
| Alfaro, V; Badiella, LI; Fernández-Hernando, N; Guil, M; Sánchez-Chapado, M | 1 |
| de la ROSETTE, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS; Wijkstra, H | 1 |
| Cotecchia, S; Goepel, M; Hein, P; Michel, MC | 1 |
| Geffriaud-Ricouard, C; Hargreave, TB; McNeill, SA; Roehrborn, CG; Santoni, J | 1 |
| McNeill, SA | 1 |
| Van Kerrebroeck, PE | 1 |
| De la Rosette, JJ; Farmer, RD; Herings, RM; Leufkens, HG; Man in 't Veld, AJ; Souverein, PC | 1 |
| Clementi, G; Costantino, G; Matera, M | 1 |
| Dutkiewics, S | 1 |
| Flannery, MT; Michel, MC; Narayan, P | 1 |
| Roehrborn, CG | 4 |
| Chess-Williams, R | 1 |
| McKeage, K; Plosker, GL | 1 |
| de la Rosette, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS | 1 |
| Jardin, A; Laval, KU; van Cangh, P; van Kerrebroec, P | 1 |
| Höfner, K; Jonas, U | 1 |
| Ahtoy, P; Chrétien, P; Delfolie, A; Dupain, T; Rauch, C; Rouchouse, A | 1 |
| Kirby, RS; Pool, JL | 1 |
| Atan, A; Başar, MM; Ozergin, O; Yildiz, M | 1 |
| Biyani, S; Elmasry, Y; Flannigan, GM; Palit, V; Puri, R; Shah, T | 1 |
| Knispel, HH; Michael, T; Miller, K; Schulte-Baukloh, H | 1 |
| Blum, RA; Marbury, TC; Pinquier, JL; Rauch, C | 1 |
| Niu, CQ; Ren, LM | 1 |
| Doherty, AP | 1 |
| Larson, TR | 1 |
| Hundt, AF; Hundt, HK; Sutherland, FC; Swart, KJ; van Essen, GH; Wiesner, JL | 1 |
| Barras, M; Palea, S | 1 |
| Bressolle, F; Costa, P; Delmas, V; Mottet, N; Robert, M | 1 |
| Armstrong, P; Borer, J | 1 |
| De Nunzio, C; Franco, G; Iori, F; Laurenti, C; Leonardo, C; Minardi, V | 1 |
| Nordling, J; Roehrborn, CG; Van Kerrebroeck, P | 1 |
| Lee, M | 1 |
| Alas, P; Helström, PJ; Mehik, A; Nickel, JC; Sarpola, A | 1 |
| Romics, I | 1 |
| Lowe, FC; Weiner, DM | 1 |
| Forrest, J; Gittelman, M; Jacobs, S; Kim, D; Marks, LS; Roehrborn, CG | 1 |
| Wyllie, MG | 2 |
| Arbilla, S; Barras, M; Galzin, AM; Mayoux, E; Pouyet, T; Ramirez, JF | 1 |
| Alexandre, L; Allard, J; Bernabe, J; Droupy, S; Giuliano, F | 1 |
| Brown, GA; Sussman, DO | 1 |
| de Reijke, TM; Klarskov, P | 1 |
| Hargreave, TB; McNeill, SA | 1 |
| Hjalmas, K; Jünemann, KP; Kramer, G; Madersbacher, H; Marschall-Kehrel, AD; Mürtz, G | 1 |
| Hayter, C; Lomaga, MA | 1 |
| Simon, HB | 1 |
| Hou, SK; Liu, SJ; Wang, XF; Wang, YC; Xu, KX | 1 |
| Basar, O; Beyazit, Y; Köklü, S; Köksal, AS; Yolcu, OF; Yüksel, O | 1 |
| Michel, MC | 1 |
| Byrne, DJ; McNeill, AS; Rizvi, S | 1 |
| Hussar, DA | 1 |
| Dessi, C; Marchese, G; Mongeau, R; Pani, L; Ruiu, S; Tambaro, S | 1 |
| Guay, DR | 1 |
| Lowe, FC | 1 |
| Hargreave, TB; McNeill, SA; Roehrborn, CG | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ | 3 |
| Jefferson, K; Okeke, A; Persad, R | 1 |
| Kähönen, M; Kööbi, T; Nieminen, T; Ylitalo, P; Ylitalo, R | 1 |
| Akbay, E; Bozlu, M; Cayan, S; Görür, S; Ulusoy, E | 1 |
| Nordling, J | 1 |
| Beaufils, P; Cabanis, MJ; Extramiana, F; Leenhardt, A; Maison-Blanche, P; Ortemann-Renon, C | 1 |
| Biyani, CS; Browning, AJ; Taylor, J | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J | 2 |
| Annemans, L; Cleemput, I; Hargreave, T; Lamotte, M; McNeill, A | 1 |
| Casey, R; Elhilali, M; Kuzmarov, I; Nickel, JC; Saad, F; Valiquette, L | 1 |
| Seftel, A | 1 |
| MacDonald, R; Wilt, TJ | 1 |
| Arunkalaivanan, A; Sinha, D | 1 |
| Biyani, CS; Elmasry, Y; Flannigan, GM; Palit, V; Puri, R; Sarkar, R; Shah, T | 1 |
| Afshari, NA; Schwinn, DA | 1 |
| Egilmez, T; Guvel, S; Kilinc, F; Ozkardes, H; Pourbagher, MA; Turunc, T | 1 |
| McVary, KT | 1 |
| Chrisofos, M; Deliveliotis, C; Dellis, A; Gougousis, E; Papatsoris, A; Varkarakis, IM | 1 |
| Irani, J | 1 |
| Nagano, M; Osada, Y; Yamaguchi, T | 1 |
| Chapple, CR; Michel, MC | 1 |
| Armitage, JN; Emberton, M | 1 |
| Michel, MC; Noguchi, Y; Ohtake, A; Okutsu, H; Sasamata, M; Someya, A; Suzuki, M; Ukai, M; Watanabe, M; Yanai-Inamura, H; Yuyama, H | 1 |
| Artibani, W; Calpista, A; Cisternino, A; De Marco, V; Iafrate, M; Prayer Galetti, T; Zeccolini, G | 1 |
| Kuritzky, L; Rosenberg, MT; Sadovsky, R | 1 |
| Fitt, AW; Settas, G | 1 |
| Fitzpatrick, JM | 1 |
| Emberton, M | 1 |
| de la Rosette, JJ; Michel, MC; van Dijk, MM | 1 |
| Clements, DG; Selinger, CP | 1 |
| De La Taille, A; Desgrandchamps, F; Doublet, JD | 1 |
| Elhilali, MM | 1 |
| O'Leary, MP | 1 |
| Elhilali, M; Emberton, M; Nickel, JC; Vallancien, G | 1 |
| Astruc, B; Cabanis, MJ; Giuliano, F; Kaplan, SA | 1 |
| Bartoletti, R; Cai, T; Carini, M; Gavazzi, A; Geppetti, P; Giubilei, G; Gontero, P; Mondaini, N; Ungar, A | 1 |
| Kwok, C; Tay, YK; Wang, YS | 1 |
| Alexandre, L; Bernabé, J; Clément, P; Denys, P; Giuliano, FA | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G | 1 |
| Lowe, FC; Santillo, VM | 1 |
| Hellstrom, WJ; Sikka, SC | 1 |
| Chapuis, F; Hennion, MC; Mullot, JU; Pichon, V; Tuffal, G | 1 |
| Ananthakrishnan, K; Fordham, MV; Manikandan, R; Qazi, HA | 1 |
| Resnick, MI; Roehrborn, CG | 1 |
| Gonzalez, RR; Kaplan, SA; Te, AE | 1 |
| Sciarra, A | 1 |
| Abdel-Aaty Shehata, M; El-Weshahy, SA; Salah Fayed, A; Yehia Hassan, N | 1 |
| Osaghae, S | 1 |
| Adibelli, FM; Akova, YA; Altan-Yaycioglu, R; Gul, U; Pelit, A; Yaycioglu, O | 1 |
| Pichon, V | 1 |
| Awan, MA; Cheung, CM; Peh, KK; Sandramouli, S | 1 |
| Brown, DJ; Mariappan, P; McNeill, AS | 1 |
| Blouin, J; Blouin, MC; Dragomir, A; Lapointe, A; Perreault, S | 1 |
| Byrne, DJ; Goodman, CM; Gopi, SS; Robertson, A | 1 |
| Ceriani, I; de Eguileor, M; Del Nero, A; Magri, V; Mangiarotti, B; Marras, E; Montanari, E; Perletti, G; Trinchieri, A; Vral, A; Zirpoli, P | 1 |
| Ceriani, I; Magri, V; Marras, E; Perletti, G; Trinchieri, A | 1 |
| Fassihi, R; Liu, Q | 2 |
| Chang, R; Chang, YW; Dong, SH; Kim, BH; Kim, HJ; Kim, SY; Kim, YW | 1 |
| Albo, G; Berardi, F; Colabufo, NA; Contino, M; de Rienzo, G; Niso, M; Pagliarulo, A; Pagliarulo, V; Perrone, R | 1 |
| Gupta, B; Gupta, VK; Singh, AK | 1 |
| Brown, AM; Chen, Y; Danthi, SJ; Eng, H; Kramer, JW; Kuryshev, YA; Lacerda, AE; Renganathan, M; Yang, T | 1 |
| Fayed, AS; Hassan, NY; Shehata, MA; Weshahy, SA | 1 |
| Noguchi, Y; Ohtake, A; Sasamata, M; Suzuki, M | 1 |
| Adayener, C; Akyol, I; Ates, F; Iseri, C; Senkul, T; Yilmaz, O | 1 |
| Gupta, R; Nair, A; Vasanti, S | 1 |
| Alexandre, L; Behr-Roussel, D; Charles Tremeaux, J; Combes, M; Giuliano, F; Gorny, D; Oger, S | 1 |
| Chang, DF; Lluel, P; Palea, S; Regnier, A; Rekik, M | 1 |
| Benemei, S; Geppetti, P; Materazzi, S; Nassini, R | 1 |
| Nickel, JC | 1 |
| Canales, BK; Feia, K; Hendlin, K; Hinck, B; Monga, M; Pedro, RN | 1 |
| Hennion, MC; Hugon-Chapuis, F; Mullot, JU; Pichon, V; Tuffal, G | 1 |
| Arikan, G; Bozkurt, O; Demir, O; Durak, I; Esen, A; Saatci, AO; Yaman, A | 1 |
| Mamalis, N | 1 |
| Bar-Yosef, Y; Kaver, I; Laufer, M; Mabjeesh, NJ; Matzkin, H; Neulander, EZ | 1 |
| Athanasopoulos, A; Giannitsas, K; Gyftopoulos, K; Perimenis, P | 1 |
| Roehrborn, CG; Rosen, RC | 1 |
| Agrawal, KC; Chandra, S; Gur, S; Hellstrom, WJ; Kadowitz, PJ; Koka, PS; Sikka, SC | 1 |
| Jangid, AG; Mistri, HN; Pudage, A; Rathod, DM; Shrivastav, PS | 1 |
| Beddingfield, R; Feia, K; Hinck, B; Kreidberg, C; Monga, M; Pedro, RN | 1 |
| Babayan, RK; Wiygul, J | 1 |
| Alexander, RB; Anderson, RU; Berger, R; Chuai, S; Krieger, JN; Kusek, JW; Landis, JR; Liong, ML; Litwin, MS; McNaughton-Collins, M; Nadler, R; Nickel, JC; Nyberg, LM; O'Leary, M; Pontari, M; Schaeffer, AJ; Shoskes, DA; White, PC; Zeitlin, S | 1 |
| Belgrano, E; Bucci, S; De Giorgi, G; Liguori, G; Maio, G; Ocello, G; Ollandini, G; Pomara, G; Trombetta, C; Vecchio, D | 1 |
| Agrawal, A; Agrawal, M; Gupta, A; Gupta, M; Lavania, P; Sarkari, A | 1 |
| Hauzeur, C; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K | 1 |
| Bacon, JA; Bridges, AS; Kasper, SC; Pollack, GM; Raub, TJ; Sawada, GA; Zhao, R | 1 |
| Chatterjee, M; Gupta, D; Gupta, S; Nanda, K; Ray, A; Singh, R; Tiwar, A | 1 |
| Wagenlehner, FM; Weidner, W | 1 |
| Alexandre, L; Behr-Roussel, D; Denoux, Y; Giuliano, F; Gorny, D; Lebret, T; Oger, S | 1 |
| Ganesh, M; Gangully, S; Kamalakannan, K; Rathinavel, G; Sivakumar, T; Tivari, R; Uppatyay, S | 1 |
| Chodchoy, V; Kongkanand, A; Lojanapiwat, B; Pumpaisanchai, S; Ratana-Olarn, K; Sae-Tang, P; Taweemonkongsap, T | 1 |
| Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY | 1 |
| Hoyano, Y; Kobayashi, S; Kusama, H; Maruyama, K; Tomiyama, Y; Yamazaki, Y | 1 |
| Jung, SW; Lee, JW; Park, SC; Rim, JS | 1 |
| Subramonian, K; Zeif, HJ | 1 |
| Cheon, J; Chung, BH; Chung, MK; Kim, MK; Kim, SW; Lee, JY; Lee, KS; Lee, SW; Park, JK; Park, K | 1 |
| García Morúa, A; Gómez Guerra, LS; Gutiérrez García, JD; Martínez Montelongo, R | 1 |
| Akarasakul, D; Choeypunt, N; Chotikawanich, E; Kongwiwatanakul, S; Leungwattanakij, S; Lojanapiwat, B; Noppakulsatit, P; Permpongkosol, S; Petchpaibuol, T; Pripatnanont, C; Tantiwong, A; Tongbai, T; Wanamkang, T; Watanachote, D | 1 |
| Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA | 1 |
| Kattan, MW; Nickel, JC; Shoskes, DA | 1 |
| Guerre, A; Hartl, DM; Katz, P | 1 |
| Chung, BH; Lee, SH; Mah, SY; Park, KK | 1 |
| André, MC; Antunes, J; Filipe, P; Pacheco, D; Silva, R; Soares de Almeida, LM | 1 |
| Kim, HS; Kim, JC; Kim, SJ; Koh, JS | 1 |
| Chatziralli, IP; Sergentanis, TN | 1 |
| Choo, MS; Han, JY; Lee, HN; Lee, KS; Lee, YS | 1 |
| Cho, JS; Choo, MS; Han, JY; Kim, JC; Lee, KS; Lee, YS; Song, K | 1 |
| Alan, C; Eren, AE; Ersay, AR; Ertung, Y; Kırılmaz, B; Koçoğlu, H | 1 |
| Andrade, RJ; Hallal, H; López Martín, A; Titos-Arcos, JC | 1 |
| Güner, E; Güner, S; Mutlu, B; Taşçi, AI | 1 |
| Bindhani, A; Mallick, S; Pattnaik, S; Swain, K | 1 |
| Atahan, Ö; Budak, YU; Karadağ, E; Öner, S | 1 |
| Calleja Aguayo, E; Delgado Alvira, R; Gracia Romero, J; Rihuete Heras, MA; Ruiz de Temiño Bravo, M | 1 |
| Evangelou, AM; Giannakopoulos, XK; Giotis, C; Karkabounas, SCh; Peschos, D; Simos, YV; Verginadis, II | 1 |
| Du, H; He, L; Ren, J; Wang, S | 1 |
| Chau, LH; Fan, CW; Fung, BT; Li, JC; Li, MK; Tai, DC | 1 |
| Atkin, SL; Aye, MM; Sathyapalan, T | 1 |
| Krilad-O-Larn, S; Permpongkosol, S; Ratana-O-Larn, K | 1 |
| Abdulkadir, NA; Cetinkaya, M; Demirturk, K; Gur, S; Hellstrom, WJ; Karabakan, M; Ozgur-Akdemir, A; Volkan-Oztekin, C | 1 |
| Akyüz, M; Güneş, M; Kalkan, S; Karaman, MI; Koca, O; Öztürk, Mİ | 1 |
| Hill, TM; McEwen, C; Sherman, JJ; Welch, RW | 1 |
| Achtsidis, V; Fountas, KN; Komninos, C; Tentolouris, N; Theodoropoulou, S; Theodossiadis, PG | 1 |
| Bączek, T; Plenis, A; Szulfer, J | 2 |
| Baldessari, A | 1 |
| Ather, MH; Nazim, SM | 1 |
| Cho, KJ; Kim, JC | 1 |
| Hwang, EC; Hwang, IS; Jung, SI; Kang, TW; Kim, MK; Kim, SO; Kwon, DD; Lu, JW; Park, K; Ryu, SB; Yu, HS | 1 |
| Hoyano, Y; Kobayashi, K; Kobayashi, M; Kuroda, J; Kusama, H; Maruyama, K; Tatemichi, S; Yokoi, R | 1 |
| Fahmy, RH | 1 |
| Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD | 1 |
| Pagariya, TP; Patil, SB | 1 |
| Lee, HJ; Lee, JW | 1 |
| Elgindy, NA; Elzoghby, AO; Samy, WM | 1 |
| Liu, Y; Mao, C; Qin, X; Yang, K; Yang, Z; Yuan, J | 1 |
| Kujala, PM; Murtola, TJ; Tammela, TL | 1 |
| Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC | 1 |
| Ahmed, S; El Zohny, SA; Mohamed, NA | 1 |
| Arora, R; Arora, V; Dey, S; Kandhwal, K; Khuroo, AH; Madan, S; Monif, T; Nazarudheen, S; Reyar, S | 1 |
| Chung, JH; Han, JH; Jo, JK; Kang, DH; Kim, TH; Lee, JW; Lee, JY; Lee, KS; Lee, SH; Lee, SW | 1 |
| Carrillo-Ruiz, JD; González-Valle, JC; Guzman-Esquivel, J; Labra-Salgado, IR; Maldonado-Ávila, M; Manzanilla-García, HA; Rosas-Nava, E; Sierra-Ramírez, JA | 1 |
| Campbell, JR; Chang, DF; Colin, J; Schweitzer, C | 1 |
| Cho, HJ; Cho, JM; Kang, JY; Moon, HS; Seo, DY; Shin, SC; Sung, LH; Yoo, TK; Yu, JH | 1 |
| Aktas, Z; Ceylan, G; Hasanreisoglu, B; Hasanreisoglu, M; Polat, F; Yuksel, N | 1 |
| Hassoun, G; Kedem, E; Nassar, L; Shahar, E | 1 |
| Fisher, E; Omar, MI; Subramonian, K | 1 |
| Burckart, GJ; Green, DJ; Hirsch, M; Karesh, A; Khurana, M; Kim, MJ; Lee, J; Momper, JD; Mulugeta, Y; Sachs, HC; Yao, L | 1 |
| Chang, Y; Du, L; Fu, Y; Gao, N; Guo, X; Wu, H; Zhang, L | 1 |
| Kara, O; Yazici, M | 1 |
| Aktas, BK; Baykam, MM; Bulut, S; Deren, T; Gokkaya, CS; Memis, A; Ozden, C; Tagci, S | 1 |
| Elsheikh, MG; Salah Azab, S | 1 |
| Altay, AB; Apaydin, E; Bademkiran, F; Cikili, N; Semerci, MB; Turna, B; Umul, M | 1 |
| Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Ryu, JK; Yang, DY; Yang, SK; Zhang, LT | 1 |
| El Said, NO; El Wakeel, L; Kamal, KM; Morad, Ael R | 1 |
| Cho, KS; Choi, YD; Ham, WS; Kang, DH; Kwon, JK; Lee, H; Lee, JY; Oh, CK | 1 |
| Gao, Y; Liu, S; Pang, Z; Yang, X; Yu, Y | 1 |
| Chen, K; Kang, R; Li, J; Liu, C; Wan, SP; Wu, W; Zeng, G | 1 |
| Barkin, J; Berner, T; Diles, D; Franks, B | 1 |
| Adbi, H; Ben Raies, N; Ben Rhouma, S; Binous, MY; H'sairi, M; Horchani, A; Mosbah, AT; Nouira, Y | 1 |
| Mallick, S; Pattnaik, S; Rao, JV; Swain, K; Varun, T | 1 |
| Bączek, T; Liu, JJ; Plenis, A; Žuvela, P | 1 |
| Dixon, S; Fraser, LA; Hayward, J; Hwang, YJ; McArthur, E; Ordon, M; Welk, B | 1 |
| Armarnik, S; Assia, EI; Mimouni, M; Rosen, E; Segev, F | 1 |
| Gupta, VR; Rudraswamy-Math, NR | 1 |
| Creta, M; Ficarra, V; Fusco, F; Giannarini, G; Longo, N; Mirone, V; Novara, G; Palmieri, A; Verze, P | 1 |
| Anoopkumar-Dukie, S; Chess-Williams, R; Forbes, A; McDermott, C | 1 |
| Conze, T; Exner, C; Kaminiarz, A; Wehrend, A | 1 |
| He, F; Li, GZ; Liu, N; Man, LB | 1 |
| Aral, A; Can Basaklar, A; Damar, C; Gulbahar, O; Karabulut, R; Kaya, C; Kose, F; Poyraz, A; Sonmez, K; Turkyilmaz, Z | 1 |
| Adamo, EB; Altavilla, D; Crea, G; Irrera, N; Lorenzini, C; Marini, H; Micali, A; Minutoli, L; Pisani, A; Puzzolo, D; Rinaldi, M; Squadrito, F; Valenti, A | 1 |
| Hammad, MA; Omar, MA; Salman, BI | 2 |
| Allenet, B; Bedouch, P; Bensalah, N; Charpiat, B; Conort, O; Garcia, S; Juste, M; Rose, FX; Roubille, R; Tod, M | 1 |
| Dogan, M; Halat, AO; Karalar, M; Keles, I; Kutluksaman, B | 1 |
| Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B | 1 |
| Cheon, J; Choi, JB; Choo, SH; Chung, BH; Kim, HJ; Kim, SW; Kim, TW; Lee, JY; Lee, KS; Lee, SW; Oh, SJ; Park, JK; Park, K; Seong, DH; Shim, KH | 1 |
| Derayea, SM; Hammad, MA; Mohamed, AA; Mohamed, AI; Omar, MA | 1 |
| Akkoc, A; Aydin, C; Baykam, MM; Ekici, M; Sentürk, AB; Yaytokgil, M | 1 |
| Afsar Yildirim, M; Akdeniz, F; Bozkurt, O; Çelik, S; Demir, O; Gursoy Bulut, M; Hacihasanoglu, ML | 1 |
| Chen, Y; Jian, Z; Li, H; Liao, B; Liu, Q; Wang, K; Yang, T | 1 |
| An, T; Cheng, G; Gao, Y; Gong, L; Sun, Y; Yu, M; Zou, M | 1 |
| Bailey, KR; Bharucha, AE; Chakraborty, S; Feuerhak, K; Harmsen, WS; Muthyala, A | 1 |
| Belal, F; Borg, H; Fathy, M; Walash, MI; Zayed, S | 1 |
| Bourdoumis, A; Buchholz, N; Dräger, D; Durner, L; Füllhase, C; Hakenberg, OW | 1 |
| Bailey, KR; Bharucha, AE; Chakraborty, S; Feuerhak, KJ; Harmsen, WS; Muthyala, A | 1 |
| Al-Jarrah, M; Al-Omari, MH; Aljarrah, Q; Alzoubi, A; Elheis, M; Jamal, A | 1 |
| Miernik, A; Praus, F | 1 |
| Hoang, P; Jacquir, S; Lemus, S; Ma, Z | 1 |
| Aboukhashaba, A; Fainberg, J; Gaffney, C; Kashanian, J; Khan, A; Pierce, H | 1 |
| Hori, Y; Ohyama, K; Sugiura, M | 1 |
| Abd El-Aziz, MF; Elnabarawi, MA; Ismail, S; Tadros, MI | 1 |
| Demirtas, A; Keske, M; Sonmez, G; Topaloglu, US | 1 |
| Rezk, MR; Tantawy, MA; Wadie, M; Weshahy, SA | 1 |
| Dahm, P; Hwang, EC; Koziarz, A; Kuntz, GM; Oestreich, MC; Sathianathen, NJ; Scales, CD; Vernooij, RW | 1 |
| Ergakov, DV; Martov, AG | 1 |
| Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ | 1 |
| Cong, BN; Duy, TN; Hoang, NN; Ivkin, DY; Krasnova, MV; Minh, TD; PhamTien, D; Povydysh, MN; Quoc, BP; Thai, HP; Thanh Ha, TN; Thi Lan, PD; Thi, HN | 1 |
| Eid, MI; El-Shabrawy, Y; Elama, HS; Shalan, SM; Zeid, AM | 1 |
| Botrè, F; Camuto, C; Comunità, F; de la Torre, X; Mazzarino, M; Stacchini, C | 1 |
| Abdel-Moety, EM; Marzouk, HM; Rezk, MR; Tantawy, MA; Wadie, M | 1 |
| Hartikainen, S; Latvala, L; Murtola, TJ; Tiihonen, M; Tolppanen, AM | 1 |
| Ayad, MM; Hosny, MM; Metias, YM | 1 |
| Ayad, MM; Hosny, MM; Hussien, EM; Metias, YM | 1 |
| Bernikov, AN; Loran, OB; Pushkar, DY | 1 |
54 review(s) available for quinazolines and alfuzosin
| Article | Year |
|---|---|
Clinical results with alpha-blockers in patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Humans; Male; Multicenter Studies as Topic; Prostatic Hyperplasia; Quinazolines; Urodynamics | 1994 |
Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1993 |
Prostatic alpha 1-adrenoceptors and uroselectivity.
Topics: Adrenergic alpha-Antagonists; Animals; Doxazosin; Humans; Male; Prazosin; Prostate; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 1997 |
Using a large clinical database to assess the effectiveness of alfuzosin.
Topics: Adrenergic alpha-Antagonists; Aged; Cost-Benefit Analysis; Databases, Factual; Decision Making, Computer-Assisted; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Surveys and Questionnaires; Treatment Outcome | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1997 |
Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Delayed-Action Preparations; Humans; Hypotension, Orthostatic; Male; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction | 1998 |
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient Selection; Plant Extracts; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1998 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizziness; Dose-Response Relationship, Drug; Doxazosin; Humans; Hypotension, Orthostatic; Male; Middle Aged; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urologic Diseases | 1999 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2000 |
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urinary Bladder; Urinary Bladder Neck Obstruction; Urination; Urine | 2001 |
Does acute urinary retention respond to alpha-blockers alone?
Topics: Acute Disease; Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention | 2001 |
Worldwide experience with alfuzosin and tamsulosin.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Controlled Clinical Trials as Topic; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urodynamics | 2001 |
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urethral Obstruction | 2001 |
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urologic Diseases | 2002 |
Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
Topics: Absorption; Adrenergic alpha-Antagonists; Aged; Area Under Curve; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Tissue Distribution | 2002 |
Alfuzosin: a clinically uroselective alpha1-blocker.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Animals; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; Urination Disorders | 2002 |
Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood-Brain Barrier; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Receptors, Adrenergic, alpha-1 | 2001 |
Current treatment options for benign prostatic hyperplasia and their impact on sexual function.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Erectile Dysfunction; Finasteride; Humans; Laser Coagulation; Male; Middle Aged; Minimally Invasive Surgical Procedures; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Behavior; Transurethral Resection of Prostate | 2003 |
Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines | 2003 |
[Pharmacologic treatment of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2003 |
Alfuzosin for the management of benign prostate hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Male; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Quinazolines | 2003 |
Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Drug Interactions; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2004 |
Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urinary Tract; Urologic Diseases | 2004 |
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urination Disorders | 2005 |
Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Time Factors | 2006 |
Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
The natural history of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Disease Progression; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
Definition of at-risk patients: dynamic variables.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Disease Progression; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination | 2006 |
Effects of alpha(1)-adrenoceptor antagonists on male sexual function.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Antagonists; Adult; Aged; Doxazosin; Ejaculation; Erectile Dysfunction; Humans; Libido; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 2006 |
Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sexual Dysfunction, Physiological; Urodynamics; Urologic Diseases | 2006 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
The management of chronic prostatitis in men with HIV.
Topics: Adrenergic alpha-Antagonists; Algorithms; Antiretroviral Therapy, Highly Active; Chronic Disease; Comorbidity; Cystoscopy; HIV Infections; Humans; Male; Pelvic Pain; Prostatitis; Quercetin; Quinazolines; Sulfonamides; Tamsulosin; Urodynamics | 2006 |
Selective sample treatment using molecularly imprinted polymers.
Topics: Benzhydryl Compounds; Cholesterol; Chromatography, Gas; Chromatography, Liquid; Phenols; Polymers; Quinazolines; Solid Phase Extraction | 2007 |
The concept of neurogenic inflammation.
Topics: Adrenergic alpha-Antagonists; Animals; Calcium Channels; Humans; Male; Nerve Tissue Proteins; Neurogenic Inflammation; Prostatism; Prostatitis; Quinazolines; Rats; Transient Receptor Potential Channels; TRPA1 Cation Channel; TRPV Cation Channels; Urinary Bladder; Urinary Bladder, Overactive | 2008 |
Role of alpha1-blockers in chronic prostatitis syndromes.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ejaculation; Humans; Male; Pelvic Pain; Prostatism; Prostatitis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Secondary Prevention; Syndrome | 2008 |
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2008 |
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.
Topics: Adrenergic alpha-Antagonists; Aged; Aging; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome | 2008 |
Watchful waiting in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Transurethral Resection of Prostate | 2009 |
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Quality of Life; Quinazolines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2009 |
Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Humans; Male; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Urinary Catheterization; Urinary Retention; Urination | 2009 |
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; Incidence; Intraoperative Complications; Iris; Iris Diseases; Odds Ratio; Phacoemulsification; Prazosin; Quinazolines; Risk Factors; Sulfonamides; Syndrome; Tamsulosin | 2011 |
Alfuzosin for the treatment of storage symptoms suggestive of overactive bladder.
Topics: Adrenergic alpha-Antagonists; Animals; Humans; Quinazolines; Urinary Bladder, Overactive | 2012 |
The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2013 |
The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Doxazosin; Humans; Indoles; Male; Quinazolines; Randomized Controlled Trials as Topic; Recovery of Function; Sulfonamides; Tamsulosin; Urinary Catheterization; Urinary Retention; Urination | 2014 |
The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo.
Topics: Adrenergic alpha-Antagonists; Bayes Theorem; Humans; Pain; Pain Measurement; Quinazolines; Randomized Controlled Trials as Topic; Stents; Sulfonamides; Tamsulosin; Treatment Outcome; Ureteral Obstruction | 2015 |
Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.
Topics: Humans; Quinazolines; Sulfonamides; Tamsulosin; Ureter; Ureteral Calculi; Urological Agents | 2015 |
α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.
Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Indoles; Male; Naphthalenes; Piperazines; Prazosin; Prostatism; Quinazolines; Severity of Illness Index; Sulfonamides; Tamsulosin; Urodynamics | 2016 |
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.
Topics: Apoptosis; Dutasteride; Endocrine System; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urological Agents | 2016 |
[How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4].
Topics: Adrenergic alpha-Antagonists; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; France; Government Agencies; Humans; Indoles; Ketoconazole; Quinazolines; Sulfonamides; Tamsulosin | 2017 |
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urological Agents | 2017 |
Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis.
Topics: Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Network Meta-Analysis; Pain; Quinazolines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Stents; Tamsulosin; Treatment Outcome; Urinary Catheterization; Urological Agents | 2019 |
The Evidence Paradox of the Effectiveness between the Paediatric and Adult Stone-Forming Population: A Narrative Review.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Age of Onset; Child; Doxazosin; Evidence-Based Medicine; Female; Humans; Male; Quinazolines; Remission Induction; Tamsulosin; Treatment Outcome; Urolithiasis; Urological Agents | 2019 |
[LUTS in BPH patients : Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms].
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphthalenes; Piperazines; Prostatic Hyperplasia; Quinazolines; Tamsulosin; Treatment Outcome; Urological Agents | 2019 |
Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxazosin; Humans; Indoles; Kidney Calculi; Lithotripsy; Middle Aged; Prazosin; Quinazolines; Randomized Controlled Trials as Topic; Tamsulosin; Ureteral Calculi | 2020 |
113 trial(s) available for quinazolines and alfuzosin
| Article | Year |
|---|---|
Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Dose-Response Relationship, Drug; Humans; Male; Quinazolines; Random Allocation; Reference Values | 1992 |
Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities.
Topics: Adrenergic alpha-Antagonists; Adult; Double-Blind Method; Humans; Male; Middle Aged; Prostatitis; Quinazolines; Syndrome; Urination; Urodynamics | 1992 |
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Time Factors; Urination; Urination Disorders; Urodynamics | 1992 |
Comparison of the new alpha 1-blocker alfuzosin with propranolol as first-line therapy in hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Propranolol; Quinazolines | 1991 |
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Time Factors; Urinary Retention; Urination | 1991 |
Efficacy of alfuzosine (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 1991 |
A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction; Urodynamics | 1985 |
[Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Europe; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Hyperplasia; Quinazolines; Random Allocation; Urination Disorders | 1988 |
Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Heart Rate; Hemodynamics; Humans; Male; Norepinephrine; Prazosin; Quinazolines; Random Allocation; Time Factors | 1989 |
Alfuzosin and the venous reflex response: studies in normal subjects.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Humans; Male; Quinazolines; Random Allocation; Reference Values; Reflex; Sympathetic Nervous System; Vasoconstriction; Veins | 1989 |
Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man.
Topics: Adult; Antihypertensive Agents; Heart Rate; Humans; Male; Phenylephrine; Pressoreceptors; Quinazolines; Reflex; Tremor | 1988 |
Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination; Urination Disorders | 1993 |
[Alfuzosin in the treatment of benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urodynamics | 1993 |
Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urodynamics | 1994 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Follow-Up Studies; Heart Rate; Humans; Long-Term Care; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination; Urodynamics | 1994 |
[Assessment of the effects of alfuzosin on miction with dynamic echography].
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Ultrasonography; Urinary Bladder Neck Obstruction; Urination | 1994 |
Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
Topics: Activities of Daily Living; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Humans; Italy; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urination; Vasodilation | 1995 |
Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Cross-Over Studies; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 1994 |
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Urination Disorders | 1995 |
Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Surveys and Questionnaires; Time Factors; Urodynamics | 1993 |
Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Surveys and Questionnaires; Time Factors | 1993 |
The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Cimetidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypotension, Orthostatic; Male; Quinazolines | 1993 |
Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy.
Topics: Adrenergic alpha-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Ejaculation; Humans; Male; Middle Aged; Prazosin; Psychotherapy; Quinazolines; Sexual Dysfunctions, Psychological | 1995 |
Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study Group.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pressure; Quinazolines; Urethra; Urinary Bladder, Neurogenic; Urodynamics | 1996 |
Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urinary Bladder Neck Obstruction; Urination Disorders; Urodynamics | 1996 |
Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Evaluation; Follow-Up Studies; France; Humans; Male; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Risk Factors; Safety | 1996 |
Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Family Practice; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexuality; Surveys and Questionnaires; Time Factors; Treatment Failure | 1996 |
Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Denmark; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Netherlands; Placebos; Prostatic Hyperplasia; Quinazolines; Time Factors | 1996 |
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Posture; Prostatic Hyperplasia; Quinazolines; Safety; Treatment Outcome; Urodynamics | 1997 |
[Role of alfuzosin in the treatment of functional voiding disorders in women].
Topics: Adolescent; Adult; Aged; Female; Humans; Middle Aged; Quinazolines; Urination Disorders | 1997 |
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-Action Preparations; Double-Blind Method; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention; Urination | 1997 |
Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Rheology; Single-Blind Method; Urinary Bladder Neck Obstruction; Urination; Urodynamics | 1997 |
Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine.
Topics: Adrenergic alpha-Antagonists; Aged; Carbachol; Diazepam; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Muscle Relaxants, Central; Parasympathomimetics; Postoperative Complications; Quinazolines; Treatment Failure; Urinary Retention; Urination | 1997 |
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urination | 1997 |
Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Hyperthermia, Induced; Male; Microwaves; Prostatic Hyperplasia; Quality of Life; Quinazolines; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome; Urination Disorders | 1998 |
Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Safety; Sexuality | 1998 |
Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Urination Disorders; Urodynamics | 1998 |
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 1998 |
Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Double-Blind Method; Humans; Hypotension; Male; Middle Aged; Placebos; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1998 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urination Disorders; Urodynamics | 1993 |
[Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Follow-Up Studies; France; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Behavior; Surveys and Questionnaires | 1999 |
Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Ejaculation; Erectile Dysfunction; Humans; Incidence; Libido; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Treatment Outcome; Urethral Obstruction | 1999 |
Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 1999 |
History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Disease Progression; Family Practice; Follow-Up Studies; Humans; Male; Prostatic Hyperplasia; Quinazolines; Time Factors; Urinary Retention | 2000 |
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Safety; Urination Disorders | 2000 |
Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
Topics: Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Blood Pressure Monitoring, Ambulatory; Delayed-Action Preparations; Evaluation Studies as Topic; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance; Prostatic Hyperplasia; Quality of Life; Quinazolines; Spain; Treatment Outcome; Urination Disorders | 2000 |
Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Time Factors | 2000 |
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Double-Blind Method; Humans; Male; Prazosin; Prostatic Hyperplasia; Quality of Life; Quinazolines; Severity of Illness Index | 2000 |
The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urination Disorders | 2000 |
The efficacy and safety of a new once-a-day formulation of an alpha-blocker.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Time Factors | 2001 |
[Long-term therapy of benign prostatic hyperplasia. Our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Mepartricin; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Time Factors | 2001 |
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Canada; Double-Blind Method; Drug Administration Schedule; Humans; Hypertension; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; United States; Urination; Urination Disorders | 2001 |
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Follow-Up Studies; Humans; Male; Middle Aged; Probability; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Treatment Outcome | 2002 |
Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Analysis of Variance; Area Under Curve; Biological Availability; Cross-Over Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 2002 |
Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Catheterization; Delayed-Action Preparations; Double-Blind Method; Humans; Male; Middle Aged; Quinazolines; Urinary Retention | 2002 |
Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.
Topics: Administration, Oral; Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Area Under Curve; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kidney; Kidney Diseases; Male; Middle Aged; Quinazolines; Receptors, Adrenergic, alpha-1; Time Factors | 2002 |
Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Biological Availability; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Preoperative Care; Probability; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Transurethral Resection of Prostate; Treatment Outcome | 2003 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention | 2003 |
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Double-Blind Method; Humans; Male; Middle Aged; Pain Measurement; Pelvic Pain; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatitis; Quinazolines; Treatment Outcome; Urodynamics | 2003 |
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Drug Administration Schedule; Humans; Hypotension; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Safety; Treatment Outcome; Urodynamics | 2003 |
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Quinazolines; Single-Blind Method; Urinary Retention | 2004 |
Prostate size influences the outcome after presenting with acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Prostate; Prostatic Hyperplasia; Quinazolines; Treatment Failure; Urinary Retention | 2004 |
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Biomarkers; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Emergencies; Humans; Life Tables; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Recurrence; Urinary Catheterization; Urinary Retention | 2005 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Pain; Penile Erection; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Bladder Neck Obstruction; Urination Disorders | 2005 |
The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Adult; Dizziness; Double-Blind Method; Female; Head-Down Tilt; Hemodynamics; Humans; Male; Quinazolines; Sulfonamides; Supine Position; Tamsulosin; Vasodilator Agents | 2005 |
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Single-Blind Method; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders | 2005 |
Clinical assessment of drug-induced QT prolongation in association with heart rate changes.
Topics: Adrenergic alpha-Antagonists; Adult; Aza Compounds; Cross-Over Studies; Double-Blind Method; Electrocardiography; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Predictive Value of Tests; Quinazolines; Quinolines; Reproducibility of Results; Treatment Outcome | 2005 |
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Organ Size; Probability; Prostatic Hyperplasia; Quinazolines; Statistics, Nonparametric; Treatment Failure; Urinary Retention | 2006 |
Is there a role for alpha1-blockers in treating double-J stent-related symptoms?
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Female; Humans; Hydronephrosis; Male; Middle Aged; Postoperative Complications; Prospective Studies; Quality of Life; Quinazolines; Stents; Ureteral Calculi | 2006 |
Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL).
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Blood Pressure; Cross-Over Studies; Delayed-Action Preparations; Dizziness; Humans; Male; Middle Aged; Phenylephrine; Quinazolines; Sulfonamides; Tamsulosin; Vascular Resistance | 2006 |
Obstructive primary bladder neck disease: evaluation of the efficacy and safety of alpha1-blockers.
Topics: Adrenergic alpha-Antagonists; Adult; Humans; Male; Middle Aged; Quinazolines; Sulfonamides; Tamsulosin; Time Factors; Urinary Bladder Neck Obstruction | 2006 |
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Risk Factors; Treatment Outcome; Urinary Retention | 2006 |
The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Pain; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urologic Diseases | 2006 |
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adrenergic alpha-Antagonists; Adult; Carbolines; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Double-Blind Method; Drug Interactions; Hemodynamics; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Quinazolines; Reference Values; Tadalafil | 2006 |
Alfuzosin (10 mg) does not affect blood pressure in young healthy men.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Heart Rate; Humans; Male; Prognosis; Prostatitis; Quinazolines; Reference Values; Ureteral Calculi | 2006 |
Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers.
Topics: Adrenergic alpha-Antagonists; Adult; Cross-Over Studies; Drug Administration Schedule; Ejaculation; Humans; Male; Quinazolines; Sperm Count; Sulfonamides; Tamsulosin; Urine | 2006 |
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prostatic Hyperplasia; Quinazolines; Urination | 2007 |
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Treatment Outcome; Urination Disorders | 2007 |
The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Intraoperative Complications; Iris Diseases; Male; Middle Aged; Phacoemulsification; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Single-Blind Method; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Visual Acuity | 2007 |
A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
Topics: Adrenergic alpha-Antagonists; Aged; Catheterization; Community Health Services; Humans; Male; Middle Aged; Outpatients; Pilot Projects; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study.
Topics: Adrenergic alpha-Antagonists; Adult; Double-Blind Method; Female; Humans; Male; Quinazolines; Ureteral Calculi | 2008 |
Effect of alfuzosin on female primary bladder neck obstruction.
Topics: Adrenergic alpha-Antagonists; Female; Humans; Middle Aged; Patient Satisfaction; Prospective Studies; Quality of Life; Quinazolines; Treatment Outcome; Urinary Bladder Neck Obstruction; Urination Disorders; Urodynamics | 2009 |
Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Prospective Studies; Quinazolines; Stents; Ureter; Young Adult | 2009 |
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; Prostatitis; Quinazolines; Severity of Illness Index; Treatment Failure; Young Adult | 2008 |
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Quinazolines; Tadalafil; Treatment Outcome; Urologic Diseases | 2009 |
Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Female; Humans; Male; Middle Aged; Prospective Studies; Quinazolines; Sulfonamides; Tamsulosin; Ureteral Calculi; Young Adult | 2009 |
Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines; Urinary Catheterization; Urinary Retention | 2009 |
The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Demography; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Postoperative Complications; Quinazolines; Stents; Surveys and Questionnaires; Tolterodine Tartrate; Young Adult | 2009 |
An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Patient Satisfaction; Prostatic Hyperplasia; Prostatism; Quinazolines; Sexual Dysfunction, Physiological; Surveys and Questionnaires | 2010 |
Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Erectile Dysfunction; Humans; Male; Middle Aged; Nocturia; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Thailand | 2010 |
Comparison of alpha-blocker, extracorporeal magnetic stimulation alone and in combination in the management of female bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Adult; Combined Modality Therapy; Female; Humans; Magnetic Field Therapy; Middle Aged; Prospective Studies; Quality of Life; Quinazolines; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder Neck Obstruction; Urodynamics | 2011 |
Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Goals; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction | 2011 |
The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Muscle Contraction; Prospective Studies; Prostatic Hyperplasia; Prostatism; Quinazolines; Time Factors; Urinary Bladder Neck Obstruction | 2011 |
Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Over Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatism; Quality of Life; Quinazolines; Severity of Illness Index; Statistics, Nonparametric; Sulfonamides; Tamsulosin; Treatment Outcome | 2011 |
Effects of pulsed electromagnetic fields on benign prostate hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Electromagnetic Fields; Humans; Male; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatism; Pulsed Radiofrequency Treatment; Quinazolines; Severity of Illness Index | 2011 |
Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Dextropropoxyphene; Diclofenac; Female; Humans; Male; Middle Aged; Pain; Prospective Studies; Quinazolines; Remission, Spontaneous; Severity of Illness Index; Ureteral Calculi; Young Adult | 2011 |
Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Thailand; Urination; Urologic Diseases | 2011 |
Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Sildenafil Citrate; Sulfones; Urination Disorders | 2012 |
Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Double-Blind Method; Female; Humans; Male; Placebos; Quinazolines; Stents; Surveys and Questionnaires; Ureter | 2012 |
Combining benefits of an adrenergic and a muscarinic blocker in a single formulation - a pharmacokinetic evaluation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Humans; Male; Muscarinic Antagonists; Quinazolines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Therapeutic Equivalency; Urological Agents; Young Adult | 2013 |
Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urodynamics | 2013 |
A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Aged; Device Removal; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Recovery of Function; Sulfonamides; Tamsulosin; Urinary Catheterization; Urinary Retention; Urination | 2014 |
Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Sectional Studies; Double-Blind Method; Humans; Intraoperative Complications; Iris Diseases; Lens Implantation, Intraocular; Male; Phacoemulsification; Prolapse; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Risk Factors; Severity of Illness Index; Sulfonamides; Tamsulosin; Video Recording | 2014 |
Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.
Topics: Benzilates; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Quinazolines; Single-Blind Method; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2014 |
The effects of tamsulosin and alfuzosin on iris morphology: an ultrasound biomicroscopic comparison.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Iris; Male; Middle Aged; Quinazolines; Sulfonamides; Tamsulosin; Ultrasonography | 2015 |
Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Dizziness; Drug Therapy, Combination; Headache; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urinary Retention | 2014 |
Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med
Topics: Aged; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urological Agents | 2015 |
Alfuzosin treatment improves the rate and time for stone expulsion in patients with distal uretral stones: a prospective randomized controlled study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Female; Humans; Male; Middle Aged; Pain; Prospective Studies; Quinazolines; Time Factors; Ureteral Calculi; Young Adult | 2015 |
Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.
Topics: Adult; Double-Blind Method; Female; Glycosaminoglycans; Hematuria; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Quinazolines; Sexual Dysfunction, Physiological; Stents; Surveys and Questionnaires; Syndrome; Treatment Outcome; Ureter; Ureteral Calculi; Ureteral Diseases; Ureteroscopy; Urinary Bladder; Urological Agents | 2016 |
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Choroid; Color Vision; Diagnostic Techniques, Ophthalmological; Humans; Iris; Male; Middle Aged; Night Vision; Organ Size; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Tamsulosin; Tomography, Optical Coherence | 2017 |
Effects of Alfuzosin, an α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Anal Canal; Constipation; Defecation; Double-Blind Method; Female; Follow-Up Studies; Habits; Humans; Male; Manometry; Middle Aged; Pressure; Quinazolines; Retrospective Studies; Treatment Outcome | 2019 |
Effects of psychosensory stimulation on anal pressures: Effects of alfuzosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Anal Canal; Defecation; Double-Blind Method; Female; Humans; Manometry; Middle Aged; Psychological Distress; Quinazolines; Rectal Diseases; Relaxation; Stroop Test | 2019 |
194 other study(ies) available for quinazolines and alfuzosin
| Article | Year |
|---|---|
Effect on cardiac sympathetic nerve activity of phenylephrine microinjected into the cat intermediolateral cell column.
Topics: Adrenergic alpha-Antagonists; Animals; Cats; Female; Heart; Phenylephrine; Quinazolines; Receptors, Adrenergic, alpha; Spinal Cord; Sympathetic Nervous System | 1992 |
[Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Premedication; Preoperative Care; Prostatectomy; Prostatic Hyperplasia; Quinazolines | 1992 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines; Radioligand Assay; Receptors, Adrenergic, alpha | 1992 |
Alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urodynamics | 1991 |
Alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1991 |
Peripubertal changes in the nature of the GnRH response to alpha-adrenoceptor stimulation in vitro and their modulation by testosterone.
Topics: Adrenergic alpha-Antagonists; Animals; Autoradiography; Hypothalamus; In Vitro Techniques; Luteinizing Hormone; Male; Orchiectomy; Phenylephrine; Pituitary Hormone-Releasing Hormones; Propranolol; Quinazolines; Radioimmunoassay; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Sexual Maturation; Testosterone | 1990 |
Direct high-performance liquid chromatographic determination of the enantiomers of alfuzosin in plasma on a second-generation alpha 1-acid glycoprotein chiral stationary phase.
Topics: Chromatography, High Pressure Liquid; Half-Life; Humans; Hydrogen-Ion Concentration; Orosomucoid; Quinazolines; Stereoisomerism | 1990 |
Effects of bethanechol and adreno-blockers on thermoregulation in spinal cord injury.
Topics: Adult; Bethanechol; Bethanechol Compounds; Body Temperature Regulation; Humans; Hypothermia; Male; Phenoxybenzamine; Quadriplegia; Quinazolines; Spinal Cord Injuries; Sympatholytics; Urinary Bladder, Neurogenic | 1989 |
Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Female; Humans; Injections, Intravenous; Male; Middle Aged; Quinazolines; Radiography; Spinal Cord Injuries; Urinary Bladder; Urination; Urination Disorders; Urodynamics | 1989 |
Improved performance of the second generation alpha 1-AGP columns: applications to the routine assay of plasma levels of alfuzosin hydrochloride.
Topics: Animals; Chromatography, High Pressure Liquid; Indicators and Reagents; Orosomucoid; Quinazolines; Rats; Spectrometry, Fluorescence; Stereoisomerism; Swine | 1989 |
High-performance liquid chromatographic determination of alfuzosin in biological fluids with fluorimetric detection and large-volume injection.
Topics: Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Drug Stability; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Quinazolines; Spectrometry, Fluorescence | 1986 |
Computerized evaluation of Valsalva's Maneuver before and during alpha-adrenoceptor blockade with alfuzosin.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Humans; Image Interpretation, Computer-Assisted; Male; Models, Biological; Quinazolines; Valsalva Maneuver | 1987 |
Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Quinazolines; Time Factors | 1988 |
A comparison of the effects of doxazosin and alfuzosin with those of urapidil on preganglionic sympathetic nerve activity in anaesthetised cats.
Topics: Action Potentials; Animals; Blood Pressure; Cats; Doxazosin; Male; Piperazines; Prazosin; Quinazolines; Receptors, Adrenergic, alpha; Sympathetic Nervous System; Vascular Resistance | 1986 |
Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives.
Topics: Animals; Chemical Phenomena; Chemistry; Hypertension; Male; Quinazolines; Rats; Rats, Inbred SHR; Structure-Activity Relationship | 1986 |
Effects of alfuzosin on urethral and blood pressures in conscious male rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dose-Response Relationship, Drug; Male; Quinazolines; Rats; Rats, Wistar; Urethra | 1995 |
[Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Time Factors | 1994 |
[Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Bladder Neck Obstruction; Urodynamics | 1995 |
[Alpha blockers, TUS-P and TUR-P in the treatment of benign prostatic hypertrophy. A comparison using multivariate statistical analysis].
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Quinazolines; Time Factors; Urodynamics | 1995 |
Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog.
Topics: Adrenergic alpha-Antagonists; Affinity Labels; Anesthesia, Endotracheal; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Doxazosin; Male; Models, Biological; Phenylephrine; Piperazines; Prazosin; Pressure; Prostate; Quinazolines; Sulfonamides; Tamsulosin | 1994 |
Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Extracellular Space; Hippocampus; Male; Microdialysis; Neostriatum; Perfusion; Prazosin; Quinazolines; Rats; Rats, Sprague-Dawley; Serotonin | 1994 |
Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract.
Topics: Adenofibroma; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Cats; Decerebrate State; Electric Stimulation; Female; Heart; Humans; In Vitro Techniques; Male; Phenylephrine; Prazosin; Prostatic Neoplasms; Quinazolines; Rabbits; Rats; Sympathetic Nervous System; Tumor Cells, Cultured; Urethra; Urinary Tract; Vasoconstriction | 1993 |
Re: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1996 |
[Drugs for prostatic adenoma].
Topics: Adrenergic alpha-Antagonists; Drug Monitoring; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1995 |
Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Doxazosin; Humans; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Phenylephrine; Prazosin; Pressure; Prostate; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 1996 |
Pharmacological characterization of alpha 1-adrenoceptor subtype mediating regulation of arterial pressure and urethral perfusion pressure in the anaesthetized rat.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dose-Response Relationship, Drug; Linear Models; Male; Phenylephrine; Prazosin; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Urethra | 1996 |
The missing alpha blocker paper.
Topics: Adrenergic alpha-Antagonists; Authorship; Humans; Publication Bias; Quinazolines; Sulfonamides; Tamsulosin | 1997 |
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Anxiety; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Humans; Longitudinal Studies; Male; Middle Aged; Perception; Prostatic Hyperplasia; Psychometrics; Quality of Life; Quinazolines; Sensitivity and Specificity; Sexual Behavior; Surveys and Questionnaires; Urination Disorders | 1997 |
Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow.
Topics: Adrenergic alpha-Antagonists; Computer Simulation; Humans; Male; Models, Biological; Observer Variation; Prostatic Hyperplasia; Quinazolines; Reproducibility of Results; Rheology; Urination; Urodynamics; Urologic Diseases | 1998 |
[The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Time Factors | 1997 |
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Male; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 1998 |
Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dose-Response Relationship, Drug; Male; Phenylephrine; Quinazolines; Rats; Rats, Wistar; Tissue Distribution; Urethra | 1998 |
Alfuzosin-associated dermatomyositis.
Topics: Adrenergic alpha-Antagonists; Aged; Dermatomyositis; Humans; Magnetic Resonance Imaging; Male; Muscle Weakness; Muscle, Skeletal; Pain; Prostatic Hyperplasia; Quinazolines | 1998 |
Alfuzosin is not associated with dermatomyositis.
Topics: Adrenergic alpha-Antagonists; Carcinoma; Dermatomyositis; Humans; Lung Neoplasms; Male; Quinazolines; Time Factors | 1999 |
Selective effects of alfuzosin and doxazosin with intraduodenal administration on urethral pressure of cats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cats; Doxazosin; Electric Stimulation; Hypogastric Plexus; Infusions, Intravenous; Male; Pressure; Quinazolines; Urethra | 1999 |
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Recurrence; Sickness Impact Profile; Urinary Retention; Urodynamics | 2000 |
Alfuzosin-induced hepatotoxicity.
Topics: Acute Disease; Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Humans; Hypertension; Male; Middle Aged; Quinazolines | 2000 |
[Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Retrospective Studies; Time Factors | 2000 |
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Prazosin; Quinazolines; Severity of Illness Index; Sulfonamides; Tamsulosin; Time Factors; Urinary Bladder Neck Obstruction; Urodynamics | 2001 |
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Chromones; Cricetinae; Dose-Response Relationship, Drug; Doxazosin; Fibroblasts; Inositol Phosphates; Phenethylamines; Prazosin; Quinazolines; Rats; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tetralones; Tritium | 2001 |
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseases; Case-Control Studies; Finasteride; Humans; Male; Middle Aged; Morbidity; Netherlands; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Research Design; Risk Factors; Sulfonamides; Tamsulosin | 2001 |
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Phytotherapy; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2001 |
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
Topics: Adrenergic beta-Antagonists; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Risk Factors; Sulfonamides; Tamsulosin; Time Factors; Treatment Failure | 2002 |
The efficacy of alfuzosin treatment in patients with prostatism.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Treatment Outcome; Urodynamics | 2001 |
Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder.
Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Cystoscopy; Female; Humans; Infant; Male; Pressure; Quinazolines; Urinary Bladder, Neurogenic; Video Recording | 2002 |
[Chiral separation and preparation of three new antagonists of alpha 1-adrenoceptors by chiral mobile phase HPLC].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Doxazosin; Molecular Structure; Prazosin; Quinazolines | 2002 |
Benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2003 |
Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma.
Topics: Adrenergic alpha-Antagonists; Chromatography, Liquid; Humans; Quinazolines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Animals; Erectile Dysfunction; Male; Muscle Relaxation; Penile Erection; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Quinazolines; Rabbits; Sildenafil Citrate; Sulfones | 2003 |
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adolescent; Adult; Advisory Committees; Anti-Infective Agents; Aza Compounds; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Approval; Electrocardiography; Fluoroquinolones; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Moxifloxacin; Phosphoric Diester Hydrolases; Piperazines; Prostatic Hyperplasia; Quinazolines; Quinolines; Risk Assessment; Sulfones; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride | 2003 |
Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Time Factors; Urinary Bladder Neck Obstruction; Urodynamics | 2003 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urinary Retention | 2003 |
Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Dopamine Agonists; Male; Penile Erection; Quinazolines; Rats; Rats, Inbred SHR | 2004 |
Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Contraindications; Drug Interactions; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2004 |
A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Ejaculation; Evoked Potentials; Male; Muscle Contraction; Pressure; Quinazolines; Rats; Rats, Wistar; Seminal Vesicles; Sulfonamides; Tamsulosin; Urinary Bladder | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders | 2004 |
[A suggested treatment algorithm in nocturnal enuresis with emphasis on partial responders].
Topics: Adolescent; Algorithms; Behavior Therapy; Benzilates; Biofeedback, Psychology; Child; Child, Preschool; Combined Modality Therapy; Deamino Arginine Vasopressin; Enuresis; Female; Follow-Up Studies; Humans; Male; Outcome and Process Assessment, Health Care; Psychotherapy; Quinazolines; Recurrence; Retreatment; Treatment Failure; Urodynamics | 2004 |
Priapism as a possible acute side effect of radical radiotherapy for prostate cancer.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Priapism; Prostate; Prostatic Neoplasms; Quinazolines; Radiotherapy; Radiotherapy Dosage | 2004 |
On call. My doctor gave me a prescription for Uroxatral to treat my enlarged prostate. I tried to look up this medicine in your Harvard Medical School Guide to Men's Health, but I couldn't find it. What can you tell me about Uroxatral?
Topics: Adrenergic beta-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2004 |
[The growth inhibition effect of alpha-adrenoceptor antagonists on androgen- independent prostate cancer cell line].
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Male; Phenoxybenzamine; Prazosin; Prostatic Neoplasms; Quinazolines | 2004 |
Alfuzosin-induced acute hepatitis in a patient with chronic liver disease.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Hepatitis B, Chronic; Humans; Liver; Liver Function Tests; Male; Quinazolines | 2004 |
Ejaculatory dysfunction and alpha-adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Ejaculation; Erectile Dysfunction; Humans; Male; Quinazolines; Sulfonamides; Tamsulosin | 2004 |
New drugs 04. Part III.
Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays.
Topics: Adrenergic alpha-Antagonists; Animals; Dose-Response Relationship, Drug; Ejaculation; Electric Stimulation; Epididymis; In Vitro Techniques; Male; Muscle Contraction; Norepinephrine; Quinazolines; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamsulosin; Vas Deferens; Vasoconstrictor Agents | 2005 |
Re: alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Quinazolines; Urinary Retention | 2005 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Probability; Prostatic Hyperplasia; Quinazolines; Reference Values; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
Re: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Quinazolines; Urinary Retention | 2005 |
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination Disorders | 2005 |
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Decision Support Techniques; Drug Costs; Emergency Treatment; Follow-Up Studies; Humans; Male; Middle Aged; Monte Carlo Method; Prostatectomy; Prostatic Hyperplasia; Quinazolines; United Kingdom; Urinary Retention | 2005 |
Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
Topics: Adrenergic alpha-Antagonists; Delayed-Action Preparations; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Urination Disorders | 2005 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Prognosis; Prospective Studies; Quinazolines; Severity of Illness Index; Treatment Outcome; Urinary Bladder Neck Obstruction; Urination Disorders | 2005 |
Urethral syndrome: response to alpha-adrenergic blocking agents.
Topics: Adrenergic alpha-Antagonists; Adult; Depression; Female; Humans; Quinazolines; Remission Induction; Sulfonamides; Syndrome; Tamsulosin; Urinary Bladder, Overactive | 2006 |
Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Follow-Up Studies; Humans; Male; Quality of Life; Quinazolines; Transurethral Resection of Prostate; Treatment Failure; Urinary Retention | 2005 |
Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Phacoemulsification; Prazosin; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2005 |
Effects of selective alpha-1-adrenergic receptor blockers on bladder weight.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Hypertrophy; Male; Middle Aged; Organ Size; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Ultrasonography; Urinary Bladder | 2006 |
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Drug Administration Schedule; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Quinazolines; Urination Disorders | 2006 |
Are all alpha-blockers created the same?
Topics: Adrenergic alpha-Antagonists; Adult; Clinical Trials as Topic; Dizziness; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2006 |
Effects of different alpha-1 adrenoceptor blockers on proximal urethral function using in vivo isovolumetric pressure changes.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cardiovascular System; Male; Phenylephrine; Prazosin; Quinazolines; Rabbits; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Urethra | 2005 |
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostatic Hyperplasia; Quinazolines; Risk Factors; Urination Disorders | 2006 |
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Libido; Male; Middle Aged; Patient Satisfaction; Penile Erection; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
What's the point?
Topics: Benzylamines; Drug Approval; Humans; Naphthalenes; Quinazolines | 2006 |
In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dose-Response Relationship, Drug; Doxazosin; Male; Prazosin; Pupil; Quinazolines; Rabbits; Receptors, Adrenergic, alpha-1; Time Factors; Urethra | 2006 |
Intraoperative floppy iris syndrome in a patient taking alfuzosin for benign prostatic hypertrophy.
Topics: Adrenergic alpha-Antagonists; Aged, 80 and over; Cataract Extraction; Humans; Intraoperative Complications; Iris; Male; Prostatic Hyperplasia; Quinazolines; Syndrome | 2006 |
Tablet induced dysphagia in oesophageal cancer.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Aged, 80 and over; Deglutition Disorders; Delayed-Action Preparations; Esophageal Neoplasms; Esophagoscopy; Humans; Male; Quinazolines; Tablets | 2006 |
The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Cross-Sectional Studies; France; Health Care Surveys; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Stents; Treatment Outcome; Urinary Catheterization; Urinary Retention | 2006 |
Toxic epidermal necrolysis caused by alfuzosin, an alpha1-adrenoceptor antagonist.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Diagnosis, Differential; Exanthema; Fever; Humans; Male; Prostatic Hyperplasia; Quinazolines; Skin Ulcer; Stevens-Johnson Syndrome | 2006 |
Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-Antagonists; Animals; Ejaculation; Male; Muscle, Skeletal; Quinazolines; Rats; Rats, Wistar; Serotonin Receptor Agonists; Sulfonamides; Tamsulosin | 2006 |
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination Disorders | 2006 |
Molecularly imprinted polymers for the clean-up of a basic drug from environmental and biological samples.
Topics: Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Humans; Polymers; Quinazolines; Soil Pollutants | 2006 |
Stuttering priapism after ingestion of alfuzosin.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Priapism; Quinazolines; Urinary Bladder Neck Obstruction | 2006 |
Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; Prevalence; Prostatic Hyperplasia; Purines; Quality of Life; Quinazolines; Risk Factors; Sildenafil Citrate; Sulfones; Urination Disorders | 2007 |
Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations.
Topics: Adrenergic alpha-Antagonists; Calibration; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Pharmaceutical Preparations; Quinazolines; Reference Standards; Sensitivity and Specificity | 2006 |
Re: Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers: W. J. Hellstrom and S. C. Sikka. J Urol 2006; 176: 1529-1533.
Topics: Adrenergic alpha-Antagonists; Ejaculation; Humans; Male; Quinazolines; Sulfonamides; Tamsulosin | 2007 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cataract Extraction; Doxazosin; Female; Humans; Hypertension; Incidence; Intraoperative Complications; Iris Diseases; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2007 |
Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Endosonography; Humans; Male; Middle Aged; Organ Size; Predictive Value of Tests; Premedication; Prognosis; Prospective Studies; Prostate; Prostatic Hyperplasia; Quinazolines; Statistics as Topic; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Catheterization; Urinary Retention; Urodynamics | 2007 |
Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Incidence; Intraoperative Complications; Iris Diseases; Male; Odds Ratio; Phacoemulsification; Postoperative Complications; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Risk Factors; Sulfonamides; Syndrome; Tamsulosin | 2007 |
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Algorithms; Androgen Antagonists; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Biomarkers, Tumor; Biopsy; Ciprofloxacin; Drug Therapy, Combination; Humans; Male; Middle Aged; Plant Extracts; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatitis; Quinazolines; Retrospective Studies; Serenoa | 2007 |
Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Androgen Antagonists; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Humans; Male; Middle Aged; Plant Extracts; Prostatitis; Quinazolines; Serenoa; Treatment Outcome | 2007 |
Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system.
Topics: Adrenergic alpha-Antagonists; Cellulose; Delayed-Action Preparations; Drug Delivery Systems; Excipients; Hydrogen-Ion Concentration; Hypromellose Derivatives; Mechanics; Methylcellulose; Polyethylene Glycols; Polymers; Quinazolines; Tablets; Water | 2008 |
Alfuzosin-induced acute liver injury.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Chemical and Drug Induced Liver Injury; Dysuria; Humans; Liver Diseases; Liver Function Tests; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 2007 |
Human epididymal and prostatic tracts of vas deferens: different contraction response to noradrenaline stimulation in isolated organ bath assay.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Aged; Dose-Response Relationship, Drug; Doxazosin; Epididymis; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Norepinephrine; Organ Specificity; Prazosin; Prostate; Quinazolines; Stimulation, Chemical; Vas Deferens | 2007 |
Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum.
Topics: Drug Evaluation, Preclinical; Electrochemistry; Electrodes; Humans; Hydrogen-Ion Concentration; Male; Molecular Structure; Pharmaceutical Preparations; Potentiometry; Prostatic Hyperplasia; Quinazolines; Reference Values; Sensitivity and Specificity | 2007 |
Alfuzosin delays cardiac repolarization by a novel mechanism.
Topics: Action Potentials; Animals; Cell Line; Female; Guinea Pigs; Humans; Long QT Syndrome; Male; Myocytes, Cardiac; Purkinje Fibers; Quinazolines; Rabbits | 2008 |
Stability-indicating spectrophotometric and spectrofluorimetric methods for determination of alfuzosin hydrochloride in the presence of its degradation products.
Topics: Adrenergic alpha-Antagonists; Calibration; Humans; Indicators and Reagents; Oxidation-Reduction; Quinazolines; Reference Standards; Solvents; Spectrometry, Fluorescence; Spectrometry, Mass, Electrospray Ionization; Tablets | 2007 |
In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dogs; Dose-Response Relationship, Drug; Ejaculation; Indoles; Male; Naphthalenes; Phenylephrine; Piperazines; Prazosin; Pressure; Prostate; Quinazolines; Sulfonamides; Tamsulosin; Urethra; Vas Deferens | 2008 |
Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Treatment Outcome | 2008 |
In vitro controlled release of alfuzosin hydrochloride using HPMC-based matrix tablets and its comparison with marketed product.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Compounding; Hypromellose Derivatives; Methylcellulose; Quinazolines; Tablets; Viscosity | 2007 |
Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum.
Topics: Adrenergic alpha-Antagonists; Carbolines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erectile Dysfunction; Humans; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Nitric Oxide; Penile Erection; Phosphodiesterase Inhibitors; Quinazolines; Tadalafil | 2008 |
Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles: possible model for intraoperative floppy-iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Intraoperative Complications; Iris; Iris Diseases; Male; Muscle, Smooth; Phenylephrine; Prostate; Quinazolines; Rabbits; Sulfonamides; Sympathomimetics; Syndrome; Tamsulosin | 2008 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturia; Patient Satisfaction; Prostatic Hyperplasia; Prostatism; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention | 2008 |
Selective and automated sample pretreatment by molecularly imprinted polymer for the analysis of the basic drug alfuzosin from plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Molecular Imprinting; Molecular Structure; Polymers; Quinazolines; Reproducibility of Results | 2008 |
The effect of various alpha1-adrenergic receptor antagonists on pupillary dilation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Iris Diseases; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2008 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2008 |
Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blotting, Western; Erectile Dysfunction; Immunohistochemistry; Male; Muscle Contraction; Muscle Relaxation; Nitric Oxide Synthase; Penile Erection; Penis; Quinazolines; Rats; Rats, Sprague-Dawley; Urinary Bladder Neck Obstruction | 2008 |
Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma.
Topics: Adrenergic alpha-Antagonists; Chromatography, Liquid; Drug Stability; Humans; Male; Methyl Ethers; Muscarinic Antagonists; Propranolol; Quinazolines; Quinuclidines; Reference Standards; Sensitivity and Specificity; Solifenacin Succinate; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tetrahydroisoquinolines | 2008 |
Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Brain; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Male; Mice; Mice, Inbred C57BL; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Osmotic Pressure; Protein Kinase Inhibitors; Quinazolines; Rats | 2009 |
Functional screening of adrenergic receptors by measuring intracellular calcium using the FlexStation scanning fluorimeter.
Topics: Animals; Biotechnology; Calcium; Cell Line; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluorometry; GTP-Binding Proteins; Humans; Kinetics; Prazosin; Protein Binding; Quinazolines; Receptors, Adrenergic; Signal Transduction; Sulfonamides; Tamsulosin | 2009 |
Prostatitis: no benefit of alpha-blockers for chronic prostatitis.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Humans; Male; Prostatitis; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Aged; Carbachol; Carbolines; Cholinergic Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electric Stimulation; Humans; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth; Norepinephrine; Phosphodiesterase 5 Inhibitors; Prostate; Quinazolines; Tadalafil; Urinary Bladder | 2010 |
Quantitation of alfuzosin hydrochloride in pharmaceutical formulations by RP-HPLC.
Topics: Adrenergic alpha-Antagonists; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Quinazolines; Sensitivity and Specificity; Tablets | 2009 |
Application of a novel symmetrical shape factor to gastroretentive matrices as a measure of swelling synchronization and its impact on drug release kinetics under standard and modified dissolution conditions.
Topics: Delayed-Action Preparations; Diltiazem; Drug Carriers; Excipients; Hypromellose Derivatives; Kinetics; Methylcellulose; Polyethylene Glycols; Povidone; Quinazolines; Solubility; Tablets; Technology, Pharmaceutical; Theophylline | 2009 |
Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Ejaculation; Humans; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 2009 |
Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Cricetinae; Doxazosin; Indoles; Male; Mesocricetus; Mice; Mice, Inbred ICR; Muscle Contraction; Norepinephrine; Prazosin; Quinazolines; Ureter | 2009 |
[Use of alfuzosin for expulsion of stones in the distal third of ureter].
Topics: Adrenergic alpha-Antagonists; Adult; Female; Humans; Male; Middle Aged; Quinazolines; Ureteral Calculi; Young Adult | 2009 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Doxazosin; Drug Contamination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tablets; Tamsulosin | 2010 |
Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Benzhydryl Compounds; Chronic Disease; Cohort Studies; Cresols; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Pain Measurement; Pelvic Pain; Phenotype; Phenylpropanolamine; Probability; Prospective Studies; Prostatitis; Quinazolines; Risk Assessment; Severity of Illness Index; Tolterodine Tartrate; Treatment Outcome; Young Adult | 2010 |
[Alpha-1-blockers (alfuzosin) for obstructive salivary gland diseases].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Colic; Constriction, Pathologic; Female; Follow-Up Studies; Humans; Hypersensitivity; Hypotension, Orthostatic; Lithotripsy; Male; Middle Aged; Parotid Diseases; Parotitis; Quinazolines; Retrospective Studies; Salivary Ducts; Salivary Gland Calculi; Salivary Gland Diseases; Submandibular Gland Diseases; Treatment Outcome | 2010 |
Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug Combinations; Humans; Hypertension; Male; Middle Aged; Models, Biological; Polypharmacy; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2010 |
Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis.
Topics: Adult; Amitriptyline; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodiazepines; Carbamazepine; Clorazepate Dipotassium; Drug Eruptions; Eosinophilia; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon-beta; Liver; Male; Multiple Sclerosis; Natalizumab; Peptides; Quinazolines; Thrombocytopenia | 2010 |
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; Endothelial Cells; Endothelium, Vascular; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Ultrasonography | 2011 |
[Recurrent hepatocellular lesion due to alfuzosin].
Topics: Adrenergic alpha-1 Receptor Antagonists; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Quinazolines; Recurrence | 2011 |
Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Male; Prostatic Hyperplasia; Quinazolines; Thrombocytopenia | 2010 |
Influence of chemical permeation enhancers on transdermal permeation of alfuzosin: an investigation using response surface modeling.
Topics: Administration, Cutaneous; Animals; Drug Delivery Systems; Female; Humans; Lauric Acids; Male; Oleic Acid; Propylene Glycol; Quinazolines; Rabbits; Skin Absorption | 2011 |
[Our experience with the use of alpha-lithic therapy in the treatment of voiding dysfunction].
Topics: Adrenergic alpha-1 Receptor Antagonists; Child; Child, Preschool; Doxazosin; Female; Humans; Male; Quinazolines; Retrospective Studies; Urination Disorders | 2010 |
Cell membrane chromatography competitive binding analysis for characterization of α1A adrenoreceptor binding interactions.
Topics: Adrenergic alpha-1 Receptor Antagonists; Binding, Competitive; Cell Line; Cell Membrane; Chromatography; Doxazosin; Humans; Methods; Phentolamine; Piperazines; Prazosin; Protein Binding; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 2011 |
Postural hypotension.
Topics: Aged; Antihypertensive Agents; Humans; Hypotension, Orthostatic; Male; Physical Examination; Quinazolines; Risk Factors | 2011 |
Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue.
Topics: Adrenergic alpha-Antagonists; Aged; Benzamides; Humans; Hyperplasia; Imatinib Mesylate; Male; Middle Aged; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Piperazines; Prostate; Prostatic Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2011 |
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Family Practice; Humans; Indoles; Male; Middle Aged; Practice Patterns, Physicians'; Prazosin; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2012 |
The effect of alpha antagonists on pupil dynamics: implications for the diagnosis of intraoperative floppy iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Case-Control Studies; Cataract Extraction; Diagnostic Techniques, Ophthalmological; Humans; Intraoperative Complications; Iris Diseases; Male; Muscle Hypotonia; Muscle, Smooth; Prospective Studies; Prostatic Hyperplasia; Pupil; Quinazolines; Sulfonamides; Tamsulosin | 2012 |
Evaluation of a column classification method using the separation of alfuzosin from its related substances.
Topics: Chromatography, Reverse-Phase; Cluster Analysis; Drug Contamination; Models, Chemical; Principal Component Analysis; Quinazolines | 2012 |
Lipases as catalysts in synthesis of fine chemicals.
Topics: Acetates; Biocatalysis; Biological Products; Candida; Diamines; Fungal Proteins; Furans; Green Chemistry Technology; Lipase; Pyridinium Compounds; Quinazolines | 2012 |
Effects of alfuzosin with methylprednisolone for spontaneous expulsion and pain control of lower ureteral stone.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Drug Therapy, Combination; Female; Humans; Male; Methylprednisolone; Middle Aged; Pain; Quinazolines; Ureteral Calculi | 2012 |
Comparison of the effects of four α1-adrenoceptor antagonists on ejaculatory function in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Ejaculation; Indoles; Male; Naphthalenes; Piperazines; Quinazolines; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamsulosin | 2012 |
Statistical approach for assessing the influence of calcium silicate and HPMC on the formulation of novel alfuzosin hydrochloride mucoadhesive-floating beads as gastroretentive drug delivery systems.
Topics: Animals; Calcium Compounds; Chemistry, Pharmaceutical; Drug Delivery Systems; Gastrointestinal Tract; Hypromellose Derivatives; Male; Methylcellulose; Quinazolines; Rats; Silicates; Tissue Adhesives | 2012 |
Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Topics: Aged; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sexual Dysfunction, Physiological; Taiwan; Treatment Outcome | 2012 |
Development and optimization of multiparticulate drug delivery system of alfuzosin hydrochloride.
Topics: Drug Delivery Systems; Microscopy, Electron, Scanning; Quinazolines; Regression Analysis; Sodium Bicarbonate | 2013 |
Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Finasteride; Glaucoma; Humans; Male; Middle Aged; Optic Neuropathy, Ischemic; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Vision Disorders | 2013 |
Novel spray-dried genipin-crosslinked casein nanoparticles for prolonged release of alfuzosin hydrochloride.
Topics: Adrenergic alpha-1 Receptor Antagonists; Caseins; Cross-Linking Reagents; Delayed-Action Preparations; Desiccation; Iridoids; Nanoparticles; Quinazolines | 2013 |
High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Cohort Studies; Disease-Free Survival; Dutasteride; Finasteride; Finland; Humans; Kallikreins; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quinazolines; Sulfonamides; Survival Rate; Tamsulosin | 2013 |
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Topics: Action Potentials; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic, Familial; Cell Differentiation; Cell Line; Cell Size; Cisapride; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Embryoid Bodies; Embryonic Stem Cells; Gene Expression Profiling; Genetic Predisposition to Disease; HEK293 Cells; Humans; In Vitro Techniques; Induced Pluripotent Stem Cells; Ion Channels; Kidney; Long QT Syndrome; Myocytes, Cardiac; Myofibrils; Nicorandil; Patch-Clamp Techniques; Quinazolines; Verapamil | 2013 |
Rapid and sensitive online determination of some selective α1-blockers by flow injection analysis with micelle-enhanced fluorescence detection.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Flow Injection Analysis; Fluorescence; Internet; Micelles; Prazosin; Quinazolines; Spectrometry, Fluorescence; Time Factors | 2013 |
Comparison of core-shell and totally porous ultra high performance liquid chromatographic stationary phases based on their selectivity towards alfuzosin compounds.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Porosity; Quinazolines; Reproducibility of Results | 2014 |
Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cerebrospinal Fluid Rhinorrhea; Doxazosin; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Rhinitis | 2014 |
Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Area Under Curve; Benzhydryl Compounds; Child; Child, Preschool; Cresols; Delayed-Action Preparations; Humans; Infant; Mandelic Acids; Marine Toxins; Muscarinic Antagonists; Oxocins; Phenylpropanolamine; Quinazolines; Tablets; Tolterodine Tartrate; Urinary Bladder, Neurogenic | 2014 |
Mixed micelle cloud point-magnetic dispersive μ-solid phase extraction of doxazosin and alfuzosin.
Topics: Calibration; Doxazosin; Humans; Hydrogen-Ion Concentration; Limit of Detection; Magnetic Phenomena; Magnetite Nanoparticles; Micelles; Quinazolines; Sodium Chloride; Sodium Dodecyl Sulfate; Solid Phase Extraction; Solvents; Spectrophotometry, Ultraviolet; Surface-Active Agents; Temperature | 2015 |
Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatectomy; Prostatic Hyperplasia; Quinazolines; Recovery of Function; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Urinary Bladder; Urodynamics; Urological Agents | 2015 |
The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Bladder; Urodynamics | 2015 |
The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Autonomic Nervous System; Blood Glucose; Body Mass Index; Erectile Dysfunction; Humans; Lipids; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Risk Factors; Sulfonamides; Tamsulosin; Testosterone | 2014 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug Therapy, Combination; Humans; Longitudinal Studies; Male; Mandelic Acids; Medication Adherence; Middle Aged; Muscarinic Antagonists; Ontario; Prazosin; Prostatic Hyperplasia; Prostatism; Pyrrolidines; Quinazolines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tolterodine Tartrate | 2015 |
[Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological | 2015 |
Temperature influencing permeation pattern of alfuzosin: an investigation using DoE.
Topics: Absorption, Physicochemical; Administration, Cutaneous; Adrenergic alpha-1 Receptor Antagonists; Cadaver; Caffeine; Cellulose; Epidermis; Hot Temperature; Humans; Membranes, Artificial; Parabens; Permeability; Pharmaceutical Vehicles; Quinazolines; Solubility; Urological Agents | 2015 |
Assessment of column selection systems using Partial Least Squares.
Topics: Chromatography; Drug Contamination; Humans; Lamotrigine; Least-Squares Analysis; Quinazolines; Triazines | 2015 |
The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study.
Topics: Accidental Falls; Adrenergic alpha-1 Receptor Antagonists; Aged; Canada; Craniocerebral Trauma; Fractures, Bone; Humans; Hypotension; Indoles; Male; Outcome Assessment, Health Care; Prostate; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Risk Factors; Sulfonamides; Tamsulosin | 2015 |
Modified corneal incisions in intraoperative floppy iris syndrome (IFIS)-prone patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Cornea; Drug Combinations; Humans; Incidence; Intraoperative Complications; Iris Diseases; Male; Middle Aged; Phacoemulsification; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2016 |
Formulation and evaluation of gastroretentive controlled release tablets of alfuzosin hydrochloride.
Topics: Acrylates; Adrenergic alpha-1 Receptor Antagonists; Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Excipients; Hypromellose Derivatives; Kinetics; Models, Chemical; Polyethylene Glycols; Quinazolines; Solubility; Tablets; Technology, Pharmaceutical; Urological Agents | 2015 |
Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Survival; Doxazosin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Male; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prazosin; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides; Tamsulosin | 2016 |
Therapy of calcium oxalate urolithiasis in a rhesus macaque (Macaca mulatta).
Topics: Animals; Cystotomy; Macaca mulatta; Male; Monkey Diseases; Nephrolithiasis; Quinazolines; Urological Agents | 2016 |
Efficacy of α-blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison.
Topics: Adrenergic alpha-Antagonists; Humans; Pain Measurement; Pain, Postoperative; Prazosin; Quinazolines; Stents; Treatment Outcome; Ureteral Obstruction | 2016 |
The effect of alfuzosin on renal resistive index, urinary electrolytes and β2 microglobulin levels and TGF β-1 levels of kidney tissue in rats with unilateral ureteropelvic junction obstruction.
Topics: Animals; beta 2-Microglobulin; Disease Models, Animal; Electrolytes; Kidney; Kidney Pelvis; Male; Quinazolines; Random Allocation; Rats; Rats, Long-Evans; Renal Artery; Transforming Growth Factor beta1; Ultrasonography, Doppler; Ureteral Obstruction | 2016 |
Utility of Hantzsch reaction for development of highly sensitive spectrofluorimetric method for determination of alfuzosin and terazosin in bulk, dosage forms and human plasma.
Topics: Adrenergic alpha-1 Receptor Antagonists; Dosage Forms; Humans; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence | 2017 |
Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Autonomic Nervous System; Heart Rate; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Quinazolines; Urination; Urodynamics; Urological Agents | 2018 |
An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.
Topics: Doxazosin; Fluorescence; Humans; Limit of Detection; o-Phthalaldehyde; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence | 2018 |
Comparison of three most frequently used alpha blocker agents in medical expulsive therapy for distal ureteral calculi, result of a retrospective observational study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Analgesics; Drug Combinations; Drug Utilization; Female; Humans; Indoles; Male; Middle Aged; Quinazolines; Retrospective Studies; Tamsulosin; Ureteral Calculi; Young Adult | 2018 |
Tadalafil versus alpha blockers (alfuzosin, doxazosin, tamsulosin and silodosin) as medical expulsive therapy for < 10 mm distal and proximal ureteral stones.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Female; Flank Pain; Humans; Indoles; Male; Middle Aged; Quinazolines; Retrospective Studies; Tadalafil; Tamsulosin; Tomography, X-Ray Computed; Treatment Outcome; Ureteral Calculi; Urological Agents; Young Adult | 2018 |
Design and optimization of gastric floating sustained-release mini-tablets of alfuzosin hydrochloride based on a factorial design: in vitro/in vivo evaluation.
Topics: Administration, Oral; Animals; Biological Availability; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Compounding; Drug Delivery Systems; Drug Design; Drug Liberation; Excipients; Gastric Mucosa; Gastrointestinal Absorption; Male; Quinazolines; Rabbits; Rats; Rats, Sprague-Dawley; Solubility; Spectroscopy, Near-Infrared; Tablets; Time Factors | 2018 |
Micellar enhanced spectrofluorimetric approach for nanogram detection of certain α
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Doxazosin; Fluorescence; Humans; Limit of Detection; Micelles; Pharmaceutical Preparations; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence; Tablets | 2018 |
Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Chromatography, High Pressure Liquid; Drug Compounding; Humans; Male; Prostatic Hyperplasia; Quinazolines; Reference Standards; Reproducibility of Results; Spectrometry, Fluorescence; Tamsulosin; Vardenafil Dihydrochloride; Vasodilator Agents | 2019 |
Successful reversal of isolated delayed spinal cord ischemia following endovascular abdominal aneurysm repair.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angiography, Digital Subtraction; Aortic Aneurysm, Abdominal; Aortography; Arterial Pressure; Blood Vessel Prosthesis Implantation; Computed Tomography Angiography; Endovascular Procedures; Fecal Incontinence; Humans; Magnetic Resonance Imaging; Male; Prostatic Hyperplasia; Quinazolines; Spinal Cord Ischemia; Time Factors; Treatment Outcome | 2019 |
Quantification of Contractile Dynamic Complexities Exhibited by Human Stem Cell-Derived Cardiomyocytes Using Nonlinear Dimensional Analysis.
Topics: Cells, Cultured; Electric Stimulation; Flecainide; Humans; Induced Pluripotent Stem Cells; Isoproterenol; Kinetics; Myocardial Contraction; Myocytes, Cardiac; Quinazolines | 2019 |
Postorgasmic illness syndrome: potential new treatment options for a rare disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Humans; Male; Orgasm; Prazosin; Quinazolines; Sexual Dysfunction, Physiological; Syndrome | 2020 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Syncope; Tamsulosin | 2019 |
Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development,
Topics: Abdomen; Adrenergic alpha-1 Receptor Antagonists; Biological Availability; Chitosan; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Monitoring; Ferrosoferric Oxide; Gastric Mucosa; Healthy Volunteers; Humans; Hypromellose Derivatives; Magnetic Resonance Imaging; Porosity; Quinazolines; Solubility; Surface Properties | 2020 |
Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Quinazolines; Severity of Illness Index; Treatment Outcome | 2020 |
A novel HPLC-DAD method for simultaneous determination of alfuzosin and solifenacin along with their official impurities induced
Topics: Chromatography, High Pressure Liquid; Kinetics; Quinazolines; Reproducibility of Results; Solifenacin Succinate | 2020 |
[The use of alfuzosin in the treatment of patients with acute urinary retention].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Transurethral Resection of Prostate; Urinary Retention | 2020 |
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Denmark; Doxazosin; Female; Follow-Up Studies; Glycolysis; Humans; Male; Middle Aged; Parkinson Disease; Prazosin; Quinazolines; Registries; Risk Factors; Tamsulosin; United States | 2021 |
Linh Phu Khang Tue Tinh inhibited prostate proliferation in rats induced benign prostatic hyperplasia by testosterone propionate.
Topics: 5-alpha Reductase Inhibitors; Animals; Dutasteride; Male; Medicine, East Asian Traditional; Prostatic Hyperplasia; Quinazolines; Random Allocation; Rats; Rats, Wistar; Testosterone Propionate; Urination; Urological Agents; Vietnam | 2021 |
Utilization of a micellar matrix for simultaneous spectrofluorimetric estimation of alfuzosin hydrochloride and vardenafil hydrochloride.
Topics: Humans; Micelles; Quinazolines; Spectrometry, Fluorescence; Tablets; Vardenafil Dihydrochloride | 2022 |
Application of liquid chromatography coupled to data-independent acquisition mass spectrometry for the metabolic profiling of N-ethyl heptedrone.
Topics: Biotransformation; Chromatography, Liquid; Cytochrome P-450 CYP3A; Designer Drugs; Female; Humans; Hydroxylation; Ketones; Male; Mass Spectrometry; Metabolome; Metabolomics; Microsomes, Liver; Molecular Structure; Psychotropic Drugs; Quinazolines | 2021 |
A sensing platform of molecular imprinted polymer-based polyaniline/carbon paste electrodes for simultaneous potentiometric determination of alfuzosin and solifenacin in binary co-formulation and spiked plasma.
Topics: Aniline Compounds; Carbon; Electrodes; Humans; Ion-Selective Electrodes; Molecular Imprinting; Polymers; Quinazolines; Solifenacin Succinate | 2022 |
Use of α1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease.
Topics: Adrenergic alpha-Antagonists; Alzheimer Disease; Case-Control Studies; Humans; Male; Quinazolines; Receptors, Adrenergic; Sulfonamides; Tamsulosin | 2022 |
Green micellar liquid chromatographic analysis of alfuzosin hydrochloride and sildenafil citrate in a binary mixture compared to classical RPLC with stability indicating studies.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Micelles; Quinazolines; Sildenafil Citrate | 2022 |
Development of green differential pulse voltammetric strategy for the determination of alfuzosin hydrochloride at pencil graphite and modified carbon paste electrodes.
Topics: Carbon; Electrochemical Techniques; Electrodes; Graphite; Quinazolines; Silica Gel; Tablets | 2022 |
[The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)].
Topics: Adrenergic alpha-Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome | 2022 |